Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 12Unknown 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 2Myeloid 2Gastrointestinal 2Plasma cell 1Other neoplasm 1Lymphoid 1Head & Neck 1Classical hematology 1

Conditions

Lung Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Radiation Injuries 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 132Cisplatin 129Pemetrexed 114Docetaxel 81Drug Therapy 62Gefitinib 57anlotinib 55Gemcitabine 55Erlotinib Hydrochloride 55Radiotherapy 48Bevacizumab 48pembrolizumab 47Paclitaxel 47Etoposide 44apatinib 42icotinib 41camrelizumab 39osimertinib 36Nivolumab 33Vinorelbine 31Radiosurgery 30sintilimab 29durvalumab 25aumolertinib 25endostar protein 24atezolizumab 22Endostatins 22toripalimab 19Blood Specimen Collection 19tislelizumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Amifostine × Thoracic × Clear all
NCT00003583 2013-12-04

Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
20 enrolled
Thoracic

Lung Neoplasms, Radiation Injuries, Drug-Related Side Effects and Adverse Reactions

NCT00004264 2013-12-04

Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡